283 related articles for article (PubMed ID: 21055184)
21. [Management of lymphoma with respect to pathologic classification: updates and controversies].
Zhu J; Song YQ
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009
[No Abstract] [Full Text] [Related]
22. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
[No Abstract] [Full Text] [Related]
23. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
24. Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome.
Alaoua A; Gilbert G; Ghannouchi N; Houchlef M; Letaief A; Bahri F
Ann Endocrinol (Paris); 2011 Jun; 72(3):247-50. PubMed ID: 21640976
[TBL] [Abstract][Full Text] [Related]
25. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Lunning MA; Armitage JO
Haematologica; 2015 Jul; 100(7):853-5. PubMed ID: 26130511
[No Abstract] [Full Text] [Related]
26. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
[TBL] [Abstract][Full Text] [Related]
27. [CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
Zheng Y; Ma XB; Jiang J; Wang YP
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):156-60. PubMed ID: 22800477
[TBL] [Abstract][Full Text] [Related]
28. Intravascular large B-cell lymphoma--a diagnostic dilemma.
Ramkumar B; Hutchison R; Khadim H; Gajra A
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e18-21. PubMed ID: 24060286
[No Abstract] [Full Text] [Related]
29. Richter syndrome in chronic lymphocytic leukaemia manifesting only as tumorous hepatomegaly.
Tadmor T; Bejar J; Attias D; Polliack A
Br J Haematol; 2011 Oct; 155(2):135. PubMed ID: 21973072
[No Abstract] [Full Text] [Related]
30. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
31. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030
[TBL] [Abstract][Full Text] [Related]
32. Isolated central nervous system relapse in a patient with systemic diffuse large B-cell lymphoma: Diagnostic and treatment challenges.
Das P; Dubashi B; Joseph D; Jain A
Indian J Cancer; 2014; 51(4):468-9. PubMed ID: 26842164
[No Abstract] [Full Text] [Related]
33. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
34. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
35. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Fowler NH
Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
[No Abstract] [Full Text] [Related]
36. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
Pfreundschuh M
J Clin Oncol; 2012 Oct; 30(28):3433-5. PubMed ID: 22949148
[No Abstract] [Full Text] [Related]
37. [ALK-positive large B-cell lymphoma: report of a case].
Yu H; Huang JX; Wang CF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):561-2. PubMed ID: 22169650
[No Abstract] [Full Text] [Related]
38. [Primary cutaneous follicle centre lymphoma: report of a case].
Rong YF; He LM; Zhang YS; Feng YZ
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):769-70. PubMed ID: 24447559
[No Abstract] [Full Text] [Related]
39. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms.
Lapa C; Knott M; Rasche L; Herrmann K; Buck AK; Rosenwald A
Eur J Haematol; 2014 Dec; 93(6):545-6. PubMed ID: 24612353
[No Abstract] [Full Text] [Related]
40. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
